IND-Enabling Development of HIV Maturation Inhibitors Formulated for use as either Oral or Long-Acting Parenterally Administered Agents

SBIR Phase Phase II award: "IND-Enabling Development of HIV Maturation Inhibitors Formulated for use as either Oral or Long-Acting Parenterally Administered Agents" awarded to DFH Pharma, Inc in Gaithersburg, Maryland. Funded by Department of Health and Human Services (National Institutes of Health). Award amount: $986,894. The SBIR/STTR programs fund innovative research and development by small businesses, with Phase I for feasibility studies and Phase II for full R&D.